
03021579

1059784

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549



NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

OMB AP	PROVAL				
OMB Number:	3235-0076				
Expires: May 31, 2002					
Estimated average burden					
hours per respon-	se16.00				

	JSE ONLY
Prefix	Senal
DATE	RECEIVED

	LL
Name of Offering (check if this is an amendment and name has changed, and indicate common Stock	change.)
Filing under (Check box(es) that apply): ☐ Rule 504 ☐ Rule 505 ☒ Rule 506 Type of Filing: ☒ New Filing ☐ Amendment	Section 4(6) ULOBRO ESSE
A. BASIC IDENTIFICATION DATA	JUN 12 2003
Enter the information requested about the issuer	7
Name of Issuer (check if this is an amendment and name has changed, and indicate Generex Biotechnology Corporation	change.) THOMSON FINANCIAL
	Telephone Number (Inclûding Area Code) 416/364-2551
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices)	Telephone Number (Including) Area Code)
Brief Description of Business Research, development, manufacture and sale of pharmaceutical products.	JUN 1 1 2003
Type of Business Organization ☐ corporation ☐ limited partnership, already formed ☐ business trust ☐ limited partnership, to be formed	(please specify).
Actual or Estimated Date of Incorporation or Organization: Month YEAR 0 9 9 7 2	
General Instructions	
Federal: Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6),	17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC. Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on the ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

CRGH

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
 - Each executive officer and director of corporate issuers and of corporate general managing partners of partnership issuers; and
 - Each general and managing partnership of partnership issuers.

Check Box(es) that Apply: Promoter Beneficial Owner		Director	☐ General and/or
			Managing Partner
Full Name (Last name first, if individual)			
Mark Fletcher			
Business or Residence Address (Number and Street, City, State, Zig	o Code)		
33 Harbour Square, Ste. 202, Toronto, Ontario_Canada M5J 2G2			
Check Box(es) that Apply: Promoter Beneficial Owner		□ Director	☐ General and/or
			Managing Partner
Full Name (Last name first, if individual)			managing raimor
Gluskin, Anna E.			
Business or Residence Address (Number and Street, City, State, Zi	p Code)		
22 Harbour Squara, Sta. 202 Taranta, Ontario, Canada, ME L2C2			
33 Harbour Square, Ste. 202, Toronto, Ontario Canada M5J 2G2 Check Box(es) that Apply: Promoter Beneficial Owner		□ Director	☐ General and/or
			Managing Partner
Full Name (Last name first, if individual)			Managing Faither
Parri Paga C			
Perri, Rose C. Business or Residence Address (Number and Street, City, State, Zi	p Code)		
22 Harbaur Causas Cha 202 Taranta Ontaria Canada ME L202			
33 Harbour Square, Ste. 202, Toronto, Ontario Canada M5J 2G2 Check Box(es) that Apply: Promoter Beneficial Owner			General and/or
			Managina Dadner
Full Name (Last name first, if individual)	<u>,</u>		Managing Partner
Madi Dankai			
Modi, Pankaj Business or Residence Address (Number and Street, City, State, Zi	p Code)		
•	,		
33 Harbour Square, Ste. 202, Toronto, Ontario Canada M5J 2G2 Check Box(es) that Apply: Promoter Beneficial Owner.	☐ Executive Officer	□ Director □ Director	General and/or
			_
Full Name (Last name first, if individual)			Managing Partner
Rosen, J. Michael Business or Residence Address (Number and Street, City, State, Zi	n Code)		
(p Code)		
33 Harbour Square, Ste. 202, Toronto, Ontario Canada M5J 2G2 Check Box(es) that Apply: Promoter Beneficial Owner	□ Evecutive Officer	⊠ Disactor	Constal and/or
Check Box(es) that Apply: Promoter Beneficial Owner	☐ Executive Officer		☐ General and/or
Full Manage (Look name Stark (Cladibidise))			Managing Partner
Full Name (Last name first, if individual)			
Bernstein, Gerald, M.D.			
Business or Residence Address (Number and Street, City, State, Zi	p Code)		
33 Harbour Square, Ste. 202, Toronto, Ontario Canada M5J 2G2			

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
 - Each executive officer and director of corporate issuers and of corporate general managing partners of partnership issuers; and
 - · Each general and managing partnership of partnership issuers.

					<u> </u>
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, i	f individual)	- ,			
Levitch, Peter					
Business or Residence Add	ress (Numb	er and Street, City, State, Zip	Code)		
33 Harbour Square, Ste.	202, Toronto, On	tario Canada M5J 2G2	_	_	
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Barratt, John P.					Wanaging Faither
Full Name (Last name first,	f individual)				
33 Harbour Square, Ste.					
Business or Residence Add	ress (Numb	er and Street, City, State, Zip	Code)		
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first,	f individual)				
Business or Residence Add	ress (Numb	er and Street, City, State, Zip	Code)		
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or
					Managing Partner
Full Name (Last name first,	if individual)				
Business or Residence Add	ress (Numb	er and Street, City, State, Zip	Code)		
			·		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	. Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)				
Business or Residence Add	ress (Numb	per and Street, City, State, Zip	Code)		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)	 			
	•				
Business or Residence Add	ress (Numb	per and Street, City, State, Zip	Code)		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

<u>, a a prejesta</u>	2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	111	В	INFORMA	TION ABO	UT OFFE	RING	54. S. A. H. A.	1.14%		7 I. M.		Taggi
1. Has th	he issuer so		s the issue	r intend to	sell, to non		d investors	in this o	offering?			Yes	No	<u> </u>
2. What	is the minir	mum inves	tment that v	will be acce	epted from	any individ	lual?						N/A	
3. Does	the offerin	g permit jo	int ownersh	nip of a sin	gle unit?	· · · · · · · · · · · · · · · · · · ·	• • • • • • • •					Yes ⊠	No	
comn offeri and/o	nission or s ing. If a pe or with a st	similar rem rson to be ate or state	ested for ea uneration fo listed is an es, list the r h a broker o	or solicitation associated name of the	on of purch I person or broker or	nases in co agent of a dealer. If	nnection w broker or more than	rith sale dealer r five (5)	s of secu egistered persons	rities I with to be	in the the SEC listed are			
	ne (Last na													
The She	emano Gro	oup, Inc.												
			ss (Numbe	er and Stree	et, City, S	tate, Zip C	ode)							
601 Cali	ifornia Str	eet, Suite	1150, San	Francisco	, CA 9410	8								
	f Associate													
The S	Shemano G	Group, Inc												
States in			d Has Solic or check ind									☐ All St	ates	
[AL] [IL] [MT] [RI]	[AK]	[AZ]	[AR]	[CA]	[CO] [] [MA] [] [TU]	[CT]	[DE]	[MA] [ND]	[FI] [MI] [OH] [WV]		[GA]	[HI]	[MO] [PA]	
Full Nan	ne (Last na	ıme first, if	individual)											
Busines	s or Reside	ence Addre	ess (Numbe	er and Stre	et, City, S	state, Zip C	ode)							
Name of	f Associate	d Broker o	r Dealer											
States in	n Which Pe	erson Liste	d Has Solic	ited or Inte	nds to Sol	icit Purchas	sers							
	(Check "A	II States" o	or check inc	dividual Sta	ites)								States	
[AL]	[AK] [[INE] [] [SC] []	[AZ]	[AR]	[CA]	[CO] [] [LA] [] [NM] [] [UT] []	[CT]	[DE] [MD] [NC] [VA] [VA]	[DC] [MA] [ND] [WA]	☐ [FI] ☐ [MI] ☐ [OH] ☐ [WV]		[GA]	[HI] [] [MS] [] [OR] [] [WY] []		
Full Nan	ne (Last na	ime first, if	individual)											
Busines	s or Reside	ence Addre	ess (Numbe	er and Stre	et, City,S	state, Zip C	ode)							
Name of	f Associate	d Broker o	r Dealer											
States in			d Has Solic or check inc									[]Aii	States	
[AL] 🗌	[AK] 🗌	[AZ] 🗀	[AR] 🗌	[CA] [[CO]	[СТ]	[DE]	[DC]	☐ [FI]		[GA] 🔲	(HI) 🗆	[ID]	
[IL]	[NE]	[IA]	[KS]	[KX]	[A] [D]	[ME] [] [VT] []	[MD] [NC] [VA]	[MA]	[FI] [MI] [OH] [WV]			[MS]	[MO]	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE. 1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box ☐ and	OF PROCEEDS	
indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	A = = = = = t =	Amount Alcond
Type of Security	Aggregate Offering Price	Amount Already Sold
Debt	\$	\$0
Equity	\$ <u>4,365,250*</u>	\$ <u>4,365,250*</u>
⊠Common ☐ Preferred		
Convertible Securities (including warrants)	\$	\$
Partnership Interests	\$0	\$
Other (Specify <u>Warrants)</u>	\$0	\$0
Total	\$ <u>4,365,250</u>	\$ <u>4,365,250</u>
 warrant for .4 shares of common stock. This filing covers the issuance of 666,667 Units of securities common stock and a currently exercisable warrant for 1 share of common stock. This filing also incommon Stock issued to the Shemano Group as part of the broker's fee. 2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." 		
Accredited Investors	9	\$ <u>4,365,250</u>
Non-accredited Investors	0	\$0
Total (for filing under Rule 504 only)		\$
Answer also in Appendix, Column 4, if filing under ULOE.	-	·
 If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. 	Type of	Dollar Amount
Type of offering	Security	Sold
Rule 505		\$
Regulation A		\$
Rule 504		\$
Total		\$
4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
Transfer Agent's Fees	⊠	\$_1,000
Printing and Engraving Costs		\$0
Legal Fees	🖂	\$ <u>5,000</u>
Accounting Fees		\$0
Engineering Fees		\$0
Sales Commissions (specify finders' fees separately)	🖂	\$ 235,567**
Other Expenses (identify) miscellaneous internal		

Salaries and fees. \$ \$ \$ Purchase of real estate. \$ \$ \$ Purchase, rental or leasing and installation of machinery and equipment \$ \$ Construction or leasing of plant buildings and facilities \$ \$ Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$ \$ Repayment of indebtedness. \$ \$ Working capital. \$ \$ Other (specify): General Corporate Funds \$ \$ Column Totals. \$ \$ \$ Total Payments Listed (column totals added) \$ \$ 4_122_183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 June 10, 2003 Title of Signer (Print or Type) Titl	tion 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the 'adjusted gross proceeds to the issuer.' 5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed discussed gross proceeds to the issuer set forth in response to Part C - Question 4.b. above. Payments to Officers, Directors, & Payments To Officers Directors, & Payments To Officers, Directors, & Payments To Officers, Directors, & Payments To Officers, Purchase of real estate. Purchase, rental or leasing and installation of machinery and equipment. Construction or leasing of plant buildings and facilities. Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger). Repayment of indebtedness. Working capital. Other (specify): General Corporate Funds Sq. 4.122.183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filled under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its stiff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) General Botechnology Corporation	14.5	CAOFFERING PRICE	NUMBER OF INVESTORS EXPE	NSES AND USE OF	RROCEEDS	
for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the bax to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part. C. Question 4.b. above. Payments to Officers, Directors, & Affiliates Purchase of real estate. Purchase, rental or leasing and installation of machinery and equipment. Construction or leasing of plant buildings and facilities. Acquisition of other business (including the value of securities of another issuer pursuant to a merger). Repayment of indebtedness. Working capital. Other (specify): General Corporate Funds The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Socurities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003	for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part . Question 4.b. above. Payments to Officers, Directors, & Affiliates Sataries and fees. Payments To Others Sataries and fees. Payments To Others Sataries and fees. Purchase of real estate. Sataries and reading and installation of machinery and equipment Sataries Sataries and reading and installation of machinery and equipment Sataries Satari	tic	on 1 and total expenses furnished in resp	conse to Part C - Question 4.a. This	difference is		\$ <u>4,122,183</u>
Salaries and fees. Salari	Salaries and fees	fo ct	r each of the purposes shown. If the amou leck the box to the left of the estimate. The	nt for any purpose is not known, furnise total of the payments listed must equi	h an estimate and		
Purchase of real estate. \$ \$ \$ Purchase, rental or leasing and installation of machinery and equipment \$ \$ Construction or leasing of plant buildings and facilities \$ \$ Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger!). \$ \$ Repayment of indebtedness. \$ \$ Working capital. \$ \$ Other (specify): General Corporate Funds \$ \$ Column Totals. \$ \$ Total Payments Listed (column totals added). \$ \$ 4.122.183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date Generas Biotechnology Corporation Title of Signer (Print or Type) Date Generas Biotechnology Corporation Title of Signer (Print or Type) Date June 10, 2003	Purchase of real estate. \$ \$ \$ Purchase, rental or leasing and installation of machinery and equipment \$ \$ Construction or leasing of plant buildings and facilities \$ \$ Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$ \$ Repayment of indebtedness \$ \$ Working capital. \$ \$ Other (specify): General Corporate Funds \$ \$ Column Totals. \$ \$ Total Payments Listed (column totals added) \$ \$ 4,122,183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to furnish to the U.S. Securities and Exchange Com	gı				Officers, Directors, & Affiliates	Others
Purchase, rental or leasing and installation of machinery and equipment \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	Purchase, rental or leasing and installation of machinery and equipment \$ \$ \$ Construction or leasing of plant buildings and facilities \$ \$ Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$ \$ Repayment of indebtedness \$ \$ Working capital \$ \$ Other (specify):		Salaries and fees		🗆 \$		L] \$
Construction or leasing of plant buildings and facilities	Construction or leasing of plant buildings and facilities		Purchase of real estate		S		□ \$
Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger). Repayment of indebtedness. \$ \$ \$ \$ \$ \$ \$ \$ \$	Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger). \$ \$ \$ \$ \$ \$ \$ \$ \$		Purchase, rental or leasing and inst	allation of machinery and equipment	t 🗆 \$		□ \$
offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger). Repayment of indebtedness. Working capital. Other (specify): General Corporate Funds Column Totals. Column Totals. Total Payments Listed (column totals added). S 4_122_183 D FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date Generas Biotechnology Corporation Title of Signer (Print or Type) Title of Signer (Print or Type)		Construction or leasing of plant build	tings and facilities	🗆 \$		\$
Repayment of indebtedness. S S S S S S S S S S S S S S S S S S	Repayment of indebtedness. \$ \$ \$ \$ \$ \$ \$ \$ \$		offering that may be used in exchan-	ge for the assets or securities of and	ther		
Working capital. S S 4.122.18 Other (specify): General Corporate Funds S S 4.122.18 Column Totals. S S 4.122.18 Total Payments Listed (column totals added). S 4.122.183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date Generax Biotechnology Corporation Title of Signer (Print or Type) Title of Signer (Print or Type)	Working capital. S S 4,122,183 Other (specify): General Corporate Funds S S 4,122,183 Column Totals. S S 4,122,180 Total Payments Listed (column totals added). S 4,122,183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date Generax Biotechnology Corporation Title of Signer (Print or Type) Title of Signer (Print or Type)		issuer pursuant to a merger)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	\$		\$
Other (specify): General Corporate Funds S 4,122,18 Column Totals. S 4,122,18 Total Payments Listed (column totals added). S 4,122,183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date Generax Biotechnology Corporation Name of Signer (Print or Type) Title of Signer (Print or Type)	Other (specify): General Corporate Funds S 4,122,183 Column Totals. S 4,122,180 Total Payments Listed (column totals added) S 4,122,183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date Generax Biotechnology Corporation Name of Signer (Print or Type) Title of Signer (Print or Type)		Repayment of indebtedness	••••••			□ \$
Column Totals. Total Payments Listed (column totals added). S \$ 4,122,183 The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Title of Signer (Print or Type)	Column Totals. Total Payments Listed (column totals added) Total Payments Listed (column totals added) Defended by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Title of Signer (Print or Type)		Working capital				□ \$
Total Payments Listed (column totals added)	Total Payments Listed (column totals added)		Other (specify):General Corr	porate Funds	□ \$		\$ 4,122,183
Total Payments Listed (column totals added)	Total Payments Listed (column totals added)						
Total Payments Listed (column totals added)	Total Payments Listed (column totals added)						□ €
Total Payments Listed (column totals added) Different Signature The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Name of Signer (Print or Type) Title of Signer (Print or Type)	Total Payments Listed (column totals added) D FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date General Biotechnology Corporation Value 10, 2003 Title of Signer (Print or Type)						
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Name of Signer (Print or Type) Title of Signer (Print or Type)	The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Title of Signer (Print or Type)						
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Name of Signer (Print or Type) Title of Signer (Print or Type)	The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Title of Signer (Print or Type)		Total Payments Listed (column total	s added)			<u>183</u>
following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Name of Signer (Print or Type) Title of Signer (Print or Type)	following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signature Date June 10, 2003 Title of Signer (Print or Type)		。 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	MANAGERAL SIGNATUR	E与特別的數量的特別	Although the Committee	The second
Generex Biotechnology Corporation Name of Signer (Print or Type) June 10, 2003 Title of Signer (Print or Type)	Generex Biotechnology Corporation Name of Signer (Print or Type) June 10, 2003 Title of Signer (Print or Type)	follo	wing signature constitutes an undertaking	g by the issuer to furnish to the U.S.	Securities and Excha	ange Commissio	on, upon written
Name of Signer (Print or Type) Title of Signer (Print or Type)	Name of Signer (Print or Type) Title of Signer (Print or Type)	Issu	er (Print or Type)	Signature	Date		
	· ·				June 10,	2003	
Mark Fletcher Vice-President and General Counsel	Mark Fletcher Vice-President and General Counsel	Nam	e of Signer (Print or Type)	Title of Signer (Print or Type)			
		Mar	k Fletcher	Vice-President and General Cou	nse)		

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

	E. STATE SIGNATURE			
Is any party described in 17 CFR 230.252 of such rule?	e(c), (d), (e) or (f) presently subject to any disqu	ualification provisions	Yes	No ⊠
	See Appendix, Column 5, for state response.			
The undersigned issuer hereby undertake Form D (17 CFR 239.500) at such times	es to furnish to any state administrator of any s as required by state law.	tate in which this notice i	s filed, a	notice on
The undersigned issuer hereby undertake issuer to offerees.	es to furnish to the state administrators, upon v	vritten request, informatio	on furnish	ed by the
Limited Offering Exemption (ULOE) of th	ne issuer is familiar with the conditions that mu e state in which this notice is filed and underst plishing that these conditions have been satisfi	ands that the issuer clain		
The issuer has read this notification and knoundersigned duly authorized person.	ws the contents to be true and has duly cause	d this notice to be signed	I on its be	half by the
Issuer (Print or Type)	Signature	Date	-	
Generex Biotechnology Corporation.				
Name (Print or Type)	Title (Print or Type)			
Gary A. Miller	Attorney			

Instruction:
Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1	2		3			4			5	
	Intend to non-ac investors (Part B-	credited in State	Type of Security and aggregate offering price offered in state (Part C-Item 1)		amount pure	investor and chased in State C-Item 2)		Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)		
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No	
AL										
AK										
AZ										
AR										
CA										
со										
СТ										
DE										
DC										
FL										
GA	l									
н										
ID	 							<u> </u>		
IL.		X	Common Stock \$1,850,000	2	\$1,850,000	0	0	J	X	
IN								<u> </u>		
IA										
KS									ļ	
KY								ļ		
LA								<u> </u>	ļ	
ME									<u> </u>	
MD								ļ		
MA									 	
МІ		<u> </u>								
MN									<u> </u>	
мѕ									 	
МО					7 of 8					

APPENDIX

1	Intend	ccredited s in State	3 Type of Security and aggregate offering price offered in state (Part C-Item 1)		amount purc	4 nvestor and chased in State C-Item 2)		5 Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)		
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No	
	163	110		investors	Amount	investors	Amount	165	100	
MT										
NE						-			-	
NV									 	
NH		 						-	-	
NJ			· · · · · · · · · · · · · · · · · · ·					ļ		
NM_			Common Stock						 	
NY	ļ	X	\$1,650,250	4	\$1,650,250	0	0	ļ	X	
NC_									ļ	
ND										
ОН									ļ	
ок			····							
OR										
РА										
RI										
sc										
SD										
TN										
TX		Х	Common Stock \$500,000	1	\$500,000	0	0		Х	
UT										
VT										
VA										
WA										
w										
WI										
WY										
PR										

APPENDIX

1	2 Intend		3 Type of Security			4		Disqual under Sta	ification ate ULOE attach	
	to non-ac investors (Part B-	credited in State	and aggregate offering price offered in state (Part C-Item 1)		Type of investor and amount purchased in State (Part C-Item 2)					
				Number of Accredited		Number of Non- Accredited				
State	Yes	No		Investors	Amount	Investors	Amount	Yes	No	
AL										
AK										
AZ										
AR										
CA								<u> </u>		
co										
СТ										
DE										
DC							 	ļ		
FL				ļ				<u> </u>		
GA				 				<u> </u>		
н				ļ						
ID			Common Stock				·	<u> </u>		
IL		_X	\$1,850,000	2	\$1,850,000	0	0	ļ	×	
IN								 		
IA_								ļ		
KS								<u> </u>		
KY								<u> </u>		
LA										
ME								<u> </u>		
MD										
MA								<u> </u>		
МІ										
MN										
MS										
МО					7 of 8					